

## LITERATURA

1. Dusek L, Muzik J, Kubasek M, et al. Epidemiology of Malignant Tumours in the Czech Republic [Internet]. Brno: Masaryk University; 2005 [cited 2023 May 3]. Available from: [www.svod.cz](http://www.svod.cz).
2. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.
3. Chowdhury N, Drake CG. Kidney Cancer: An Overview of Current Therapeutic Approaches. Urol Clin North Am. 2020;47(4):419-431.
4. Larcher A, Fallara G, Rosiello G, et al. Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. Eur Urol. 2020;78(3):321-326.
5. Poprach A, Holanek M, Chloupkova R, et al. Cytoreductive nephrectomy and overall survival of patients with metastatic renal cell carcinoma treated with targeted therapy – data from the national renal registry. Cancers (Basel). 2020;12(10).
6. Escudier BJ, Rini BI, Martini J-F, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. J Clin Oncol [Internet]. 2017;35(15\_suppl):4508. Available from: [http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15\\_suppl.4508](http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4508).
7. Haas NB, Manola J, Dutcher JP, et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017;3(9):1249-1252.
8. Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol. 2017;35(35):3916-3923.
9. Ryan CW, Tangen CM, Heath EI, et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2023;402(10407):1043-1051.
10. Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet (London, England). 2022;400(10358):1103-1116.
11. Allaf ME, Kim SE, Master VA, et al. PROSPER: Phase III Randomized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). J Clin Oncol [Internet]. 2021;39(15\_suppl):TPS4596–TPS4596. Available from: [https://doi.org/10.1200/JCO.2021.39.15\\_suppl.TPS4596](https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4596).
12. Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2023;401(10379):821-832.
13. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683-694.
14. Choueiri TK, Tomczak P, Park SH, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024;390(15):1359-1371.



Pro vás  
a vaše pacienty  
vysíláme  
**PODCASTY**

NOVĚ:

**Kdy nám zdravotní  
a sociální systém podává  
pomocnou ruku?**

Medicínské informace ze Solenu můžete získávat nejen v tištěné podobě, na kongresech nebo z on-line kurzů, ale máme i podcastový kanál.

Více na **[www.solen.cz](http://www.solen.cz)**



V podcastových aplikacích hledejte **HOVORY O MEDICÍNĚ**